SAKARPharmaceuticals
Sakar Healthcare Ltd — PE Ratio & Valuation Analysis
₹498.45
-2.69%
Current P/E44.17xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E33.3x32.4% above avg
⚠️
39.0% Premium to Industry
SAKAR P/E 44.17x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2024 | ₹5.63 | ₹296 | 52.7x |
| 2023 | ₹6.86 | ₹400 | 58.3x |
| 2022 | ₹10.09 | ₹224 | 22.2x |
| 2021 | ₹708.58 | ₹163 | 0.2x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Sakar Healthcare Ltd Valuation
Sakar Healthcare Ltd (SAKAR) currently trades at 44.17x earnings. The Pharmaceuticals sector average PE is 31.77x. SAKAR commands a premium, reflecting high growth expectations. Historically, SAKAR has traded at an average PE of 33.3x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
6.48%
Dividend Yield
0.00%
More on Sakar Healthcare Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.